The next chapter of radiopharmaceutical therapy starts now

Leading-edge technologies in the fight against cancer

We are a next generation radiopharmaceutical company, taking cancer head on.

For what’s ahead

Precision is the future of cancer care. Radiopharmaceutical products could offer new hope to patients with cancer.

What to expect

Treatments in development

We are pushing forward the next-generation of radiopharmaceuticals with our exciting pipeline.

About our Pipeline

Focused treatment

With focus and precision, our products direct the power of high energy particles towards cancer - and only cancer.

Learn the science

Clinical trials

Learn more about our ongoing study for Men with Metastatic Castration-Resistant Prostate Cancer. Now enrolling in phase 3.

Splash trial

News + Stories

Press Release
2 Feb
2023

POINT Biopharma to Participate in Upcoming Investor Conferences

POINT today announced management will participate in the following upcoming investor conferences

Press Release
12 Jan
2023

POINT Biopharma Completes Randomization in PNT2002’s Phase 3 SPLASH Trial

Enrollment for the randomization phase of SPLASH completed prior to EOY 2022, meeting previous guidance